CLOVER HEALTH INVESTMENTS, CORP. /DE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wai Conrad (CEO, Counterpart Health) sold 300,000 indirectly-held shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.72 ($1.42M total) on 2026-09-15 under a Rule 10b5-1 trading plan.
Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.
Clover Health's (CLOV) VP of Finance, Joseph Oldakowski, sold 20,000 shares on September 14, 2026, reducing his holdings to 279,067 shares. This follows a pattern of insider selling, with 29 sales and no purchases in the past year. The stock trades at $5.16, with a market cap of $2.71 billion, and is considered modestly overvalued by GuruFocus's valuation model.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning CLOV (CLOVER HEALTH INVESTMENTS, CORP. /DE). Coverage has skewed bearish: 2 bullish, 2 neutral, and 3 bearish.
Recent CLOV coverage spans financial news, insider activity and market movers.
In the last 30 days, CLOV insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($1.6M). The most active reporter was Soares Karen, Chief Legal Officer, with 1 filing. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal reduced confidence, potential short-term pressure on the stock.
Higher exposure to Medicare Advantage could tighten profit margins.
Insider sale may signal weak confidence, but size is modest relative to market cap.
Insider sale by a senior finance officer may signal limited confidence in near‑term performance.
Analyst upgrade and higher price target suggest near-term upside.
AlphAI scores every news story that mentions CLOV with an AI model for sentiment and relevance, and aggregates insider trades from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Wai Conrad (CEO, Counterpart Health) sold 300,000 indirectly-held shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.72 ($1.42M total) on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readSeveral healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.
2 min readClover Health's (CLOV) VP of Finance, Joseph Oldakowski, sold 20,000 shares on September 14, 2026, reducing his holdings to 279,067 shares. This follows a pattern of insider selling, with 29 sales and no purchases in the past year. The stock trades at $5.16, with a market cap of $2.71 billion, and is considered modestly overvalued by GuruFocus's valuation model.
2 min readOLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 20,000 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $5.16 ($0.10M total) on 2026-09-14.
1 min readClover Health (CLOV) shares rose after Deutsche Bank initiated coverage with a Buy rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company shows rapid membership and revenue growth, a debt-free balance sheet, and solid cash generation, but faces challenges in achieving steady profits and managing medical-cost uncertainty.
1 min readClover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.
2 min readAnalysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.
3 min readProgyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.
3 min readClover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.
3 min readClover Health (CLOV) officer Brady Priest filed a Rule 144 notice to sell up to 73,516 shares, valued at $305,113.45, by 08/31/2026. Priest previously sold 474,801 shares for $2.17M on 08/14/2026 and 441,601 shares for $2.14M on 08/07/2026. CLOV has 435.44M shares outstanding.
1 min read
